Friedlaender, A. ., Metro, G. ., Signorelli, D. ., Gili, A. ., Economopoulou, P. ., Roila, F. ., … Addeo, A. . (2020). Impact of performance status on non-small-cell lung cancer patients with a PD-L1 tumour proportion score ≥50% treated with front-line pembrolizumab. Acta Oncologica, 59(9), 1058–1063. https://doi.org/10.1080/0284186X.2020.1781249